influenza

Influenza prevention in older adults moves forward with disclosure of the DANFLU-2 protocol comparing high-dose versus standard-dose vaccines in an individually randomized, pragmatic framework. The design emphasizes broad eligibility and real-world outcomes...

Influenza in older adults continues to drive severe illness and healthcare use. A pragmatic, individually randomized comparison of high-dose versus standard-dose influenza vaccination centers on real-world effectiveness outcomes captured via registries, pos...

The DANFLU-2 trial evaluates high-dose versus standard-dose influenza vaccination in older adults using a pragmatic, individually randomized, registry-enabled design. By embedding allocation in routine care and capturing outcomes via national registries, it...

In influenza prevention for older adults, a national pragmatic, individually randomized comparison of high-dose versus standard-dose vaccine outlines a registry-embedded design that aligns outcomes with hospitalizations and mortality. The approach emphasize...